Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance

Advances in Clinical and Experimental Medicine

Volumn 21, Issue 5, 2012, Pages 671-680

  Iwańczak, Franciszek ^a   Iwańczak, Barbara ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Helicobacter pylori; Resistance; Sequential therapy; Treatment

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BISMUTH SALT; CIPROFLOXACIN; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; GENTAMICIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RIFAMPICIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; VOMITING;

EID: 84870376293     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Hunt RH, Xiao SD, Mégraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelhol G, Fock M, Fedain S, Cohen H, Malfartheiner P, Vakil N, Hamid S, Goh KL, Wong BCY, Krabshuis J: Helicobacter pylori in developing countries World Gastroenterol Organization Global Guideline 2010, 1-15.
2. Łaszewicz W: Wyniki badań nad zakażeniem Helicobacter pylori. Trans Humana Białystok 2004.
3. Marshall BJ, Warren JR: Unidentified cerved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1, 1311-1315.
4. Suerbaum S, Michetti P: Helicobacter pylori infection. N Engl Med 2002, 347, 1175-1186.
5. Bornschein J, Rokkas T, Selgrad M, Malfertheiner P: Gastric cancer: clinical aspects, epidemiology and molecular background. Helicobacter 2011, 16 (Supl. 1), 45-52.
6. Gonzalez CA, Figueiredo C, Lic CB, Ferreira RM, Pardo ML, Ruiz Liso JM, Alonso P, Sala N, Capella G, Sanz-Anquela JM: Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-ries area in Spain. Am J Gastroenterol 2011, 106, 867-874.
7. Wróblewski LE, Peek RM Jr, Wilson KT: Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010, 23, 713-739.
8. Backert S, Clyne M: Pathogenesis of Helicobacter pylori infection. Helicobacter 2011, 16 (Suppl.1), 19-25.
9. Graham DY, Shiotani A: New concepts of resistance in the treatment of Helicobacter pylori infections. Nature Clin Pract Gastroenterol Hepat 2008, 5, 6, 321-331.
10. Song Z, Zhou L, Wang Y, Xue Y, Bai P, Lin S, He L, Zhang J, Xu Z, Huo X, Xiong L, Chen M, Du Y, Li Z: A study to explore Hp antibiotic resistance and efficacy of eradication therapy in China (multicenter, nation-wide, randomized, control study). Helicobacter 2011, 16, (Suppl. 1), 117 Abstract no.: PO 7.05.
11. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY: Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010, 8, 36-41.
12. Mahachaj V, Ratanachu-Ek T, Vilaichone R: Nation-wide survey of antibiotic resistant Helicobacter pylori in Thailand. Helicobacter 2011, 16 (Suppl.1), 117, Abstract no.: PO7.01.
13. Schwarzer A, Bontems P, Urruzuno P, Kalach N, Iwańczak B, Roma-Glannikou E, Sykora J, Kindreman A, Casswali T, Koletzko S: Sequental therapy as first line treatment in children with new diagnosed symptomatic H. pylori infection. Helicobacter 2011, 16(Suppl.1), 85, Abstract no.: WS4.2.
14. Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, Gottrand F, Celińska-Cedro D, Roma-Giannikou E, Orderda G, Kolacek S, Urruzuno P, Martinez-Gómez MJ, Casswali T, Ashorn M, Bodanszky H, Mégraud F: Prospective multicenter study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006, 55, 1711-1716.
15. Moon BS, An B, Kim H, Lim HC, Lee YC, Lee G, Kim S, Park M, Kim JB: Antibiotic resistance and eradication rate of Helicobacter pylori strains isolated in Korean patients. Helicobacter 2011, 16, Sept. Suppl. 1, 119, Abstract no.: PO 7.13.
16. Martinez-Gonzalez B, Papadokos K, Konstontoilaki A, Michopoulus S, Roma E, Sgouras DN, Mentis AF: Primary antibiotic resistance and Helicobacter pylori. Virulence factors - is there an association? Helicobacter 2011, 16 Suppl 1, 118 Abstract no.: PO 7.07.
17. Mégraud F: H. pylori antibiotic resistance: prevalence, importance and advances in testing. Gut 2004, 53, 1374-1384.
18. Dzierzanowska-Fangrat K, Rozynek E, Celińska-Cedro D, Jarosz M, Pawłowska J, Szadkowski A, Budzyńska A, Nowak J, Romańczuk W, Prosiecki R, Jóźwiak P, Dzierżanowska D: Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study. Int J Antimicrob Agents 2005, 26, 230-234.
19. Gosciniak G, Iwańczak B, Przondo-Mordarska A, Grabińska J, Iwańczak F: Ocena wrażliwości szczepów Helicobacter pylori na wybrane chemioterapeutyki. Pediatr Pol 2001, 76, 873-877.
20. Gościniak G: Rodzaj Helicobacter pylori - implikacje kliniczne i narastaja̧cy problem oporności. Pediatr Współ Gastroenter Hepat Żyw Dziecka 2010, 12, 41-44.
21. Gosłciniak G, Błernat M, Blaszczuk J, Kania A, Grabińska J, Poniewierka E: The primary resistance of H. pylori strains in adults. Helicobacter 2011, 16 suppl. 1, 120 Abstract no.: PO 7.15.
22. Fischbach L, Evans EL: Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007, 26, 343-357.
23. Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, Chong S, Colletti RB, Casswali T, Elitsur Y, Guarner J, Kalach N, Madrazo A, Megraud F, Oderda G: H. pylori Working Groups of ESPGHAN and NASPGHAN evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011, 53, 230-243.
24. Dzieniszewski J, Jarosz M oraz Grupa Robocza PTG-E do spraw zakazenia Helicobacter pylori. Ustalenia Grupy Roboczej PTG-E dotycza̧ce postȩpowania w zakażeniu Helicobacter pylori - Consensus 2008. Gastroenterol Pol 2008, 15, 323-331.
25. Malfertheiner P, Mègraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ: The European Helicobacter Study Group (EHSG): Current concept in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007, 56, 772-781.
26. Chey WD, Wong BC: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007, 102, 1808-1825.
27. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salverno R, Marmo R, Federico A, Nardone G: Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010, 59 (11), 1465-1470.
28. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre B, Duenas C, Mateos-Rodriguez JM, Gonzalez-Garcio G, Abadia EG, Gispert JP: Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regiment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010, 31, 1077-1084.
29. Malfertheiner P, Bazzoli F, Delchier JC, Celiński K, Giguère M, Rivière M, Mègraud F: Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole and tetracycline-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011, 377, 905-913.
30. O'Connor A, Gisbert JP, McNamara D, O'Morain C: Treatment of Helicobacter pylori infection 2011. Helicobacter 2011, 16 (Suppl. 1), 53-58.
31. Schwarzer A, Urruzuno P, Iwańczak B, Martinez-Gomez MZ, Kalach N, Roma-Giannikou E, Liptay S, Bontems P, Buderus S, Wenzl TG, Koletzko S: New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr 2011, 52, 424-428.